Citi Remains Bullish on Argenx SE (ARGX)

Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to buy. Citi analyst Samantha Semenkow maintained a Buy rating on Argenx SE (NASDAQ:ARGX) on October 23 and set a price target of $1,041. Argenx SE (NASDAQ:ARGX) also received a rating update from Bank of America Securities analyst Tazeen Ahmad, who reiterated a Buy rating on the stock and lifted the price target to $942 from $887.

Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain?

Ahmad based the positive rating on the company’s strong performance and the growth potential of its Vyvgart medication. The analyst stated that Argenx SE (NASDAQ:ARGX) reported impressive Q2 revenues for Vyvgart, exceeding expectations with a 20% quarter-over-quarter growth.

The Q3 revenue is expected to surpass $1 billion, supported by the drug’s expansion into new geographical regions and the approval of a prefilled syringe, which is anticipated to boost its usage and accessibility.

Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.

While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.